Product Images Lenalidomide

This seems to be a medical report indicating the survival probability of individuals with an illness. The report includes percentage values for survival probability, progression-free survival in months, and the number of subjects at risk. There are also comparisons made between different groups, such as RD Continuous vs. RD18, and MPT. There is no indication of what illness is being referred to.*

The text shows a graph comparing the time to progression in months for two treatments, Lenalidomide/Dex and Plagebo/Dex. The graph shows a significant difference between the two treatments with a p-value of less than 0.001. The HR (hazard ratio) for Lenalidomide/Dex compared to Plagebo/Dex is 0.285 with a 95% confidence interval of 0.210-0.386. The proportion of subjects at different time points is also shown in percentages: 10%, 25%, 50%, and 75%.*

This is a survival analysis of patients treated with Lenalidomide/Dex for a certain medical condition. The results show a Hazard Ratio (HR) of 0.324 with a 95% confidence interval (CI) of 0.240-0.438, indicating a significant reduction in progression of the disease in patients who received this treatment. The Log Rank p-value is less than 0.001, supporting the significance of the results. Time to progression data is presented graphically, indicating the number of months until patients progressed on the treatment.*

Each capsule of Lenalidomide contains 10mg and should be stored in a controlled room temperature of 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). This medicine is only available by prescription and has a potential for human birth defects. The accompanying Medication Guide should be dispensed to each patient. The manufacturer is Natco Pharma Limited, located in Visakhapatnam, India, and the medicine is distributed by Teva Pharmaceuticals in Parsippany, New Jersey. The product is serialized with the code 40100045.*

Each capsule of this medication contains 15mg of Lenalidomide and should be stored between 20°C to 25°C (68°F to 77°F). Excursions are allowed to 15°C to 30°C (59°F to BE°F). This medication may cause potential for human birth defects so a Medication Guide must be dispensed to each patient. It is recommended to see prescribing information for dosing and administration. The medicine is manufactured by Natco Pharma Limited in India for Teva Pharmaceuticals in Parsippany, Nj 07054. The NDC (National Drug Code) number is 0480-1244-21 and the product is RX only.Serialization Coding Area is also mentioned.*

Each capsule of Lenalidomide 25 mg should be stored at a controlled room temperature between 20°C to 25°C (68°F to 77°F), with permitted excursions to 15°C to 30°C (59°F to 86°F). The medication guide should be dispensed to each patient as it carries a warning of potential human birth defects. The prescription drug is available in a container containing 21 capsules, with the manufacturer being Natco Pharma Limited from Visakhapatnam, India, and it is manufactured for Teva Pharmaceuticals. The serialization coding area is also provided.*